Immuron

Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US

Retrieved on: 
Thursday, March 7, 2024
CHIM, Placebo, USD, Otto, ETEC, Diarrhea, Gastrointestinal tract, Food, Treatment, BLA, Enterotoxigenic Escherichia coli, Bacteria, ASX, Food and Drug Administration, Patient, IMC, Disease, Biologics license application, Infection, Trial of the century, Immuron, Pharmaceutical industry

MELBOURNE, Australia, March 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce the interim topline results confirming that a single daily dose of Travelan® is effective in prevention of moderate to severe diarrhea following challenge with enterotoxigenic Escherichia coli (ETEC).

Key Points: 
  • This interim analysis summarizes the data for a total of 60 subjects who have completed the inpatient challenge component of this current clinical study.
  • Last patients last visits are anticipated to commence in April this year and final clinical study report will be completed in H2 2024.
  • To learn more about Phase 2 study design, read: U.S. Food and Drug Administration Step 3: Clinical Research
    IMM-124E (Travelan®) will be the first product developed with Immuron’s platform technology to proceed into Phase 3 clinical trials.
  • Immuron is in the process of exploring non-dilutive funding opportunities for these Phase 3 clinical trials.

Immuron achieves record Travelan® sales

Retrieved on: 
Tuesday, February 13, 2024
YTD, Growth, ASX, Immuron, Australian Bureau of Statistics, International Trade Administration, IMC, Statistics, McKesson Corporation, Uranium mining

MELBOURNE, Australia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record sales (unaudited net sales) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract.

Key Points: 
  • MELBOURNE, Australia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record sales (unaudited net sales) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract.
  • Sales of Travelan® increased to AUD $2.1 million YTD Jan 2024 compared to AUD $0.3 million YTD Jan 2023.
  • Flavio Palumbo, Chief Commercial Officer said, “We are excited by the strong sales results on Travelan®.
  • Immuron’s investment to drive awareness of the Travelan® brand has seen strong sales results in Australia over the summer peak travel period.

Immuron achieves record half yearly Travelan® sales

Retrieved on: 
Tuesday, January 16, 2024
ASX, Immuron, Statistics, International Trade Administration, Travel, IMC, TGA, Australian Bureau of Statistics

MELBOURNE, Australia, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record half yearly sales (unaudited net sales) of its over-the-counter gastrointestinal and digestive health immune supplement Travelan®.

Key Points: 
  • Total sales of A$2,355,580 in H1, FY24
    51% higher than pre-pandemic period H1, FY20 sales
    MELBOURNE, Australia, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record half yearly sales (unaudited net sales) of its over-the-counter gastrointestinal and digestive health immune supplement Travelan®.
  • Sales of Travelan® increased to AUD $1,853,048 in H1, FY24, compared to AUD $260,205 in H1, FY23.
  • Sales increased by $1,054,164 (132%) on the pre-pandemic peak period (H1, FY20).
  • Immuron anticipates sales to grow strongly closer to the peak spring / summer travel period.

Immuron Clinical Trials Update

Retrieved on: 
Friday, December 22, 2023
Spore, Clostridioides difficile, ASX, Immuron, Principal, Diarrhea, FDA, NMRC, Campylobacter, IMC, Johns Hopkins University, Trial of the century, MD, Agriculture, Clinical trial, GLP, Volunteering, Escherichia, Escherichia coli, CIR, CHIM, Patient, Monash University, Safety, JHU, Clostridioides, Pharmaceutical industry

MELBOURNE, Australia, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to provide shareholders and the market with an update on the company’s clinical development portfolio.

Key Points: 
  • The NMRC has recently completed the in-patient stage of the campylobacter challenge clinical study.
  • Headline results from the clinical trial are anticipated to be reported in H2 2024.
  • The Phase 2 clinical trial is designed to evaluate the safety and protective efficacy of the new product manufactured by Immuron compared to a placebo in a controlled human infection model (CHIM).
  • The inpatient challenge phase of the Travelan clinical study led by Principal Investigator Dr Mohamed Al-Ibrahim at the Pharmaron CPC FDA inspected Clinical Research Facility Inpatient Unit located in Baltimore, Maryland US, has been completed.

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Retrieved on: 
Monday, December 4, 2023
ASX, Immuron, Principal, IBS, Diarrhea, NMRC, ETEC, Campylobacter, Disease, IMC, Trial of the century, Johns Hopkins University, MD, Clinical trial, Enterotoxigenic Escherichia coli, Infection, Morale, CIR, CHIM, Gastroenteritis, Safety, JHU, Judgement, Pharmaceutical industry

MELBOURNE, Australia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that the US Naval Medical Research Command (NMRC) has initiated the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) developed in collaboration with Immuron. The NMRC has prioritized the clinical development of the study to evaluate the efficacy of the new therapeutic product to prevent infectious diarrhea caused by Campylobacter.

Key Points: 
  • The NMRC has prioritized the clinical development of the study to evaluate the efficacy of the new therapeutic product to prevent infectious diarrhea caused by Campylobacter.
  • The clinical study is being led by Principal Investigator Dr Kawsar Talaat, MD at the Johns Hopkins University (JHU) Center for Immunization Research (CIR) Inpatient Unit, located at the JHU Bayview Medical Campus, Baltimore, Maryland.
  • The dosing, challenge and the in-patient stage of the study is anticipated to be completed by the third week of December 2023.
  • The estimated study completion date (last participant, last visit) is June 2024 with headline results from the clinical trial expected to be reported in 2H 2024.

Immuron Announces Travelan® Clinical Study Cohort 2 commences

Retrieved on: 
Wednesday, October 18, 2023
ASX, Principal, ETEC, FDA, Trial of the century, Enterotoxigenic Escherichia coli, Morale, Immuron, Diarrhea, Disease, Judgement, CHIM, Clinical trial, Patient, IBS, Safety, Gastroenteritis, IMC, Pharmaceutical industry

MELBOURNE, Australia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce the second cohort of 34 participants have commenced the clinical trial to evaluate the efficacy of Travelan® to prevent infectious diarrhea caused by enterotoxigenic Escherichia coli (ETEC).

Key Points: 
  • The clinical study is being led by Principal Investigator Dr Mohamed Al-Ibrahim at the Pharmaron CPC FDA inspected Clinical Research Facility Inpatient Unit located in Baltimore, Maryland US.
  • The Phase 2 clinical trial is designed to evaluate the safety and protective efficacy of Travelan® compared to a placebo in a controlled human infection model (CHIM).
  • The first cohort in-patient stage of the study was completed in August 2023.
  • Immuron received confirmation that a second cohort of 34 study participants were admitted to the Pharmaron inpatient facility and randomized to receive either Travelan® or placebo.

Immuron achieves record quarterly Travelan® sales

Retrieved on: 
Wednesday, October 11, 2023
International Trade Administration, Pharmacy, ASX, TGA, Statistics, Travel, IMC, Immuron, Therapeutic Goods Administration, AUD, Australian Bureau of Statistics, Mobile phone, Amazon

MELBOURNE, Australia, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record quarterly sales (unaudited net sales) of its over-the-counter gastrointestinal and digestive health immune supplement Travelan®.

Key Points: 
  • Total sales of A$1,565,767 in Q1, FY24
    130% higher than pre-pandemic period Q1, FY20 sales
    MELBOURNE, Australia, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record quarterly sales (unaudited net sales) of its over-the-counter gastrointestinal and digestive health immune supplement Travelan®.
  • Immuron has since supplied product to wholesalers who in turn have supplied retail pharmacies.
  • Sales of Travelan® increased to AUD $1,339,160 in Q1, FY24, compared to AUD $25,565 in Q1, FY23.
  • Immuron anticipates sales to grow strongly closer to the peak spring / summer travel period.

Immuron Limited Announces Participation in the LD Micro Main Event XVI

Retrieved on: 
Monday, September 18, 2023
Immuron, Friends, Sweet Sixteen, Main, Research, Department of Defense Architecture Framework, Extrapyramidal system

Presentation on Wednesday, October 4th at 11:00 PT

Key Points: 
  • "We know what this event means to our industry and how much people enjoy attending.
  • I am honored to host our close friends and allies for our "Sweet Sixteen" installment of the Main Event," stated Chris Lahiji, Founder of LD Micro.
  • The 2023 LD Micro Main Event XVI will run from October 3rd to the 5th at the Luxe Sunset Boulevard Hotel in Los Angeles.
  • This three-day event will feature around 200 companies, presenting in half-hour increments, and attending private meetings with investors.

Immuron achieves record monthly Travelan® sales

Retrieved on: 
Wednesday, September 13, 2023
Immuron, IMC, Travel, Pharmacy, Statistics, Australian Bureau of Statistics, Therapeutic Goods Administration, ASX, AUD, TGA, Financial adviser, Tourism, Amazon

MELBOURNE, Australia, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record monthly sales (unaudited net sales) of its over-the-counter gastrointestinal and digestive health immune supplement Travelan®.

Key Points: 
  • MELBOURNE, Australia, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record monthly sales (unaudited net sales) of its over-the-counter gastrointestinal and digestive health immune supplement Travelan®.
  • Immuron has since supplied product to wholesalers who in turn have supplied retail pharmacies.
  • Sales of Travelan® increased by 7984% in August 2023 to AUD $1.18 M, compared to AUD $14,581 in August 2022.
  • Immuron anticipates sales to grow strongly closer to the peak spring / summer travel period.

Immuron to present at the Military Health System Research Symposium

Retrieved on: 
Monday, August 14, 2023
Immuron, IMC, Naval Medical Research Center, Enterotoxigenic Escherichia coli, U.S. Department of Defense Strategy for Operating in Cyberspace, Diarrhea, Campylobacter, Gastroenteritis, ETEC, ASX, Traveler, Judgement, Development, IBS, Disease, NMRC, Poster, Morale, MTEC, Pharmaceutical industry

The company will attend the meeting as an Exhibitor and present two posters at the event.

Key Points: 
  • The company will attend the meeting as an Exhibitor and present two posters at the event.
  • One entitled ‘Clinical Evaluation of an Oral prophylactic for prevention of Travelers diarrhea in active-duty military assigned abroad’.
  • The Naval Medical Research Center (NMRC) are also presenting a poster at the symposium on the new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) developed in collaboration with Immuron.
  • The NMRC poster is entitled ‘Research and Development of Hyperimmune Bovine Colostrum Products for the Prevention of Travelers’ Diarrhea’.